Genmab — Januar 2018

[royal]

Want to build your own "Powerhouse"?

[nohope]

Probably just hoping for a paycheck - every month. I know the feeling.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[Parasitism]

god morgen

[DevOp]

God morgen, itf kombi med PD1/PD-L1 tror jeg først, at vi ser statistiske resultater, der viser en evt forskel - altså ikke historier om enkelte pts forløb. Det må være dybde af respons, OR og ikke mindst længde af respons, der ser ud til at blive forbedret, når Dara for alvor kommer i spil ved opregulering af CD38 - hvor PD1 inhibitors ellers normalt ser ud til at miste virkningen.

[Mcjean]

Go'morgen der falder en bombe i US i dag se link i aktiesnakken, korruption på højeste niveau i administrationen i US, hele det socialistiske, globalistiske korthus vælter i aften med Hillary, Obama og FBI i spidsen. Overvældende beviser og masser af informanter i FBI.

[transalp]

go morgen

[Sukkeralf]

ClinicalTrials.gov

(clinicaltrials.gov)

[Sukkeralf]

Humax IL8 er ikke helt død endnu

[E_L]

oh that is a nice find! I was just looking at genmab website yesterday, i think they just updated/ maintained a bit http://www.genmab.com/product-pipeline/products-in-development

[JKY_VH]

Kan kun læse overskriften https://medwatch.dk/secure/Medicinal___Biotek/article10243049.ece?utm_source=Feed&utm_medium=latest

[pauly]

Ya it looks good

[Parasitism]

Det er ikke meget der sker i chatten i dag. Did you drink too many heineken last night E L?

[bongobob]

GEN patent på HER2 ADC! Hvor passer den ind pre clinical? http://www.freshpatents.com/-dt20180125ptan20180022816.php

[Sukkeralf]

de har også taget på HER2 CD3

[gentogen]

Jeg mener ikke, at det er er ADC. Citat: "It is an object of the present invention to provide novel highly specific and effective monoclonal HER2 antibodies for medical use"

[E_L]

it is not an easy text to read... they try to keep as many options open as they can within the patent description i guess. very interesting though.

[E_L]

no Para, i am fine lol, just 1.

[Bulder]

Men senere står der: ...high capacity for killing cancer cells expressing high or low levels of HER2 when administered as an antibody drug conjugate (ADC), no substantial agonistic effect on the proliferation of HER2-expressing cancer cells, and provide for effective ADCC-mediated killing of HER2-expressing cells, as well as any combination of the foregoing properties.